Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-Class T Cell Receptor Natural Killer (TCR-NK) Cell Therapy for Multiple Myeloma

Replay and The University of Texas MD Anderson Cancer Center announced that the US FDA has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered TCR-NK cell therapy for relapsed or refractory multiple myeloma.